AL amyloidosis is a rare disease where abnormal proteins called light chains build up in organs, causing damage. The EUREKA study will create a registry, or a list, of new cases of AL amyloidosis in Europe. This will help doctors understand the disease better using advanced science tools. The study will also use big data analysis (which means looking at a lot of information) and artificial intelligence (computer programs that can learn) to help with diagnosis and treatment.

• The study is for people who are 18 or older and have not been treated for AL amyloidosis.
• Participants must agree to be followed up at a center that's part of the study.
• The goal is to help find better ways to diagnose and treat AL amyloidosis early.

This study could help improve how doctors find and treat AL amyloidosis, but you must be okay with sharing your health information and samples. If you meet the criteria and are interested, talk to your doctor about joining.